Freestone Grove Partners LP Akebia Therapeutics, Inc. Transaction History
Freestone Grove Partners LP
- $13.4 Trillion
- Q3 2025
A detailed history of Freestone Grove Partners LP transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 202,122 shares of AKBA stock, worth $343,607. This represents 0.0% of its overall portfolio holdings.
Number of Shares
202,122Holding current value
$343,607% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AKBA
# of Institutions
185Shares Held
122MCall Options Held
202KPut Options Held
234K-
Vanguard Group Inc Valley Forge, PA15.5MShares$26.4 Million0.0% of portfolio
-
State Street Corp Boston, MA11.8MShares$20.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$19.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.18MShares$10.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$9.77 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $313M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...